Description
Roy S. Herbst, MD, PhD, and Corey J. Langer, MD, discuss the FDA approval of upfront carboplatin/pemetrexed with pembrolizumab for non–small cell lung cancer, as well as data from the KEYNOTE-021 trial cohort G and the impact on clinical practice.
Tags
cancer oncology